Objective/Scope
The purpose of this article is to determine whether or not Applichem should keep their production of
Release-Ease within their current plants or move production to another location. This new location
would be one, or more, of Applichems’ production locations including: Gary (Indiana/USA), Mexico,
Frankfurt (Germany/Europe), Sunchem (Japan). To determine this, a cost analysis must be conducted to
verify the benefits of keeping production of Release-Ease in their current locations, or moving
production to another location. When determining the cost benefits, transportation and production cost
differences must be considered.
Recommendations
Through careful analysis, it is recommended that Production of Release-ease be maintained in Gary,
Indiana. Instead of abandoning the Gary production facility due to its lack of production efficiencies,
measures to improve the facility should be implemented.
Ceasing production of Release-ease in Japan is also recommended. Although the plant in Japan is more
technologically advanced, its high production costs and low productivity levels are valid reasons for
eliminating the Release-ease production lines. It is recommended, however, that the plant continues its
current production of the other product it manufactures. The plant will also be useful in conducting
R&D for other Applichem products.
Changes in the production volumes among the various plants are also recommended. These changes will
increase production to full capacity for some plants while reducing transportation costs.
Analysis
Cost Analysis
The first observation that can be made about Applichem’s current production is the amount of excess
capacity that could be used in its Frankfort, Gary and Mexico plants. (Exhibit 2) Import duty costs, as
well as, important transportation costs have to be minimized in order to optimize efficiency of the
manufacturing. Three different analyses were performed to evaluate the costs of manufacturing; if Gary
was shutdown (Exhibit 3), a cost optimization was calculated (Exhibit 1), and status quo was maintained
(Exhibit 2).
At the current level, it costs Applichem $83 million to produce and ship its worldwide production. To
shut down Gary, every other plant would have to be used at maximum capacity and total costs would
increase by $4 million per year if demand stayed constant. The cost optimization analysis suggested that
the Japanese plant should not be used to manufacture the Release-ease product. The cost decrease
generated by the plant closure would be around $4 million from its current costs.
By eliminating the production in Japan, volumes would have to be readjusted in the other plants. Both
Gary and the Frankfort plants would have to operate at full capacity. Reduction in production at the
Mexico plant was forecasted to reduce overall costs. This would give Applichem excess capacity that it
could use again in the future if demand were to grow.
Keeping the Gary plant protects Applichem from exchange rate risk when importing in the US.
Importing all of the US demand would expose Applichem to a lot of variability in its costs and revenues